Download
12916_2024_Article_3771.pdf 2,34MB
WeightNameValue
1000 Titel
  • Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial
1000 Autor/in
  1. Wagner, Robert |
  2. Buettner, Janine |
  3. Heni, Martin |
  4. Fritsche, Louise |
  5. Kullmann, Stephanie |
  6. Wagmüller, Moritz |
  7. Peter, Andreas |
  8. Preißl, Hubert |
  9. Machann, Jürgen |
  10. Jumpertz von Schwartzenberg, Reiner |
  11. Birkenfeld, Andreas L. |
  12. Pape, Ulrich-Frank |
  13. van Hall, Gerrit |
  14. Plomgaard, Peter |
  15. Häring, Hans-Ulrich |
  16. Fritsche, Andreas |
  17. Thompson, Kelsey N. |
  18. Klein, Reinhild |
  19. Stefan, Norbert |
1000 Verlag BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-11-26
1000 Erschienen in
1000 Quellenangabe
  • 22(1):558
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12916-024-03771-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590543/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>The potential impact of specific food additives, common in Western diets, on the risk of developing type 2 diabetes is not well understood. This study focuses on carrageenan, a widely used food additive known to induce insulin resistance and gut inflammation in animal models, and its effects on human health.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>In a randomised, double-blind, placebo-controlled, cross-over trial conducted at a university hospital metabolic study centre, 20 males (age 27.4 ± 4.3 years, BMI 24.5 ± 2.5 kg/m<jats:sup>2</jats:sup>) participated. The intervention involved oral intake of carrageenan (250 mg) or placebo in the morning and in the evening and each intervention lasted 2 weeks. The primary outcome measured was insulin sensitivity (using oral glucose tolerance test [OGTT] and hyperinsulinaemic-euglycaemic clamp). Additional end-points included whole body and hepatic insulin sensitivity, MRI-measured brain inflammation and insulin resistance, intestinal permeability (via lactulose-mannitol test and plasma zonulin levels), and gut microbiome composition. Immune-cell activation and pro-inflammatory cytokine release from peripheral blood mononuclear cells were measured.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Overall insulin sensitivity did not show significant differences between the treatments. However, interactions between BMI and treatment were observed (OGTT-based insulin sensitivity index: <jats:italic>p</jats:italic>=0.04, fasting insulin resistance: <jats:italic>p</jats:italic>=0.01, hepatic insulin sensitivity index: <jats:italic>p</jats:italic>=0.04). In overweight participants, carrageenan exposure resulted in lower whole body and hepatic insulin sensitivity, a trend towards increased brain inflammation, and elevated C-reactive protein (CRP) and IL-6 levels compared to placebo. Additionally, carrageenan was associated with increased intestinal permeability. <jats:italic>In vitro</jats:italic> natural killer (NK-)cell activation and increased pro-inflammatory cytokine release were found after carrageenan exposure in the participant’s peripheral blood mononuclear cells.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>These findings suggest that carrageenan, a common food additive, may contribute to insulin resistance and subclinical inflammation in overweight individuals through pro-inflammatory mechanisms in the gut. Further investigation into the long-term health impacts of carrageenan and other food additives is warranted.</jats:p> </jats:sec><jats:sec> <jats:title>Trial registration</jats:title> <jats:p>NCT02629705.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Double-Blind Method [MeSH]
lokal Type 2 diabetes
lokal Emulsifiers
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Insulin sensitivity
lokal Carrageenan/administration
lokal Gastrointestinal Microbiome [MeSH]
lokal Gut microbiome
lokal Cytokines/blood [MeSH]
lokal Male [MeSH]
lokal Cross-Over Studies [MeSH]
lokal Glucose Tolerance Test [MeSH]
lokal Research
lokal Young Adult [MeSH]
lokal Insulin Resistance/physiology [MeSH]
lokal Intestinal permeability
lokal Carrageenan
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/V2FnbmVyLCBSb2JlcnQ=|https://frl.publisso.de/adhoc/uri/QnVldHRuZXIsIEphbmluZQ==|https://frl.publisso.de/adhoc/uri/SGVuaSwgTWFydGlu|https://frl.publisso.de/adhoc/uri/RnJpdHNjaGUsIExvdWlzZQ==|https://frl.publisso.de/adhoc/uri/S3VsbG1hbm4sIFN0ZXBoYW5pZQ==|https://frl.publisso.de/adhoc/uri/V2FnbcO8bGxlciwgTW9yaXR6|https://frl.publisso.de/adhoc/uri/UGV0ZXIsIEFuZHJlYXM=|https://orcid.org/0000-0002-8859-4661|https://frl.publisso.de/adhoc/uri/TWFjaGFubiwgSsO8cmdlbg==|https://frl.publisso.de/adhoc/uri/SnVtcGVydHogdm9uIFNjaHdhcnR6ZW5iZXJnLCBSZWluZXI=|https://frl.publisso.de/adhoc/uri/Qmlya2VuZmVsZCwgQW5kcmVhcyBMLg==|https://frl.publisso.de/adhoc/uri/UGFwZSwgVWxyaWNoLUZyYW5r|https://frl.publisso.de/adhoc/uri/dmFuIEhhbGwsIEdlcnJpdA==|https://frl.publisso.de/adhoc/uri/UGxvbWdhYXJkLCBQZXRlcg==|https://frl.publisso.de/adhoc/uri/SMOkcmluZywgSGFucy1VbHJpY2g=|https://frl.publisso.de/adhoc/uri/RnJpdHNjaGUsIEFuZHJlYXM=|https://frl.publisso.de/adhoc/uri/VGhvbXBzb24sIEtlbHNleSBOLg==|https://frl.publisso.de/adhoc/uri/S2xlaW4sIFJlaW5oaWxk|https://frl.publisso.de/adhoc/uri/U3RlZmFuLCBOb3JiZXJ0
1000 Hinweis
  • DeepGreen-ID: f24524a78094496689dbdb0050944afa ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6494036.rdf
1000 Erstellt am 2025-02-04T00:29:00.343+0100
1000 Erstellt von 322
1000 beschreibt frl:6494036
1000 Zuletzt bearbeitet 2025-09-14T18:18:34.747+0200
1000 Objekt bearb. Sun Sep 14 18:18:34 CEST 2025
1000 Vgl. frl:6494036
1000 Oai Id
  1. oai:frl.publisso.de:frl:6494036 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source